CLOSTRIDIUM BUTYRICUM MIYAIRI 588
Metastatic Clear Cell Renal Cell Carcinoma
City of Hope Medical Centerother_biologicalPhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 58/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Metastatic Clear Cell Renal Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
lu-177-dota-girentuximab Radboud University Medical Center | Phase 2 | B |
Yivoximab Sun Yat-sen University | Phase 2 | CCC |
PSMA I&T Centre Leon Berard | Phase 1/2 | CCC |
Hydroxychloroquine Abramson Cancer Center at Penn Medicine | Phase 1/2 | CCC |
ly2510924 Eli Lilly and Company | Phase 2 | CCC |
lutetium (<sup>177</sup>Lu) zadavotide guraxetan Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1/2 | CCC |
PIFLUFOLASTAT Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1/2 | CCC |
Valemetostat M.D. Anderson Cancer Center | Phase 1 | CC |
Same molecule, other indications
CLOSTRIDIUM BUTYRICUM MIYAIRI 588 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →